What drove the revenue growth in the first quarter of 2002?

Revenue growth was primarily driven by the Companion Animal Group (CAG) with increased sales of VetTest slides and veterinary reference laboratory services, and the Food and Environmental Group (FEG) with higher sales of livestock testing products and water testing products.

Why did net income and EPS decrease despite revenue growth?

The decrease in net income and EPS was primarily due to a $2.9 million pre-tax charge related to the CEO succession in January 2002. Additionally, there were unfavorable variances and product mix shifts within the CAG segment, impacting gross profit.

What is the impact of adopting SFAS No. 142 on the company's financials?

The adoption of SFAS No. 142, effective January 1, 2002, resulted in the cessation of goodwill amortization, which was approximately $1.1 million for the quarter. This change reduced operating expenses and contributed to a lower effective tax rate (34% vs. 36% in the prior year). The company must now perform an impairment review of goodwill.

How is the company managing its inventory, particularly concerning new products and potential obsolescence?

Inventories are stated at the lower of cost or market. The company is managing significant inventory related to the nitazoxanide product awaiting FDA approval, and has provided reserves for potential losses if not approved. They also have substantial slide inventory for chemistry instruments with shelf-life considerations and component parts for the new LaserCyte hematology instrument, for which they expect to recoup costs upon launch but acknowledge potential write-offs if development or market acceptance falters.

IDXX 10-Q Quarterly Report Q1 FY2002 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. reported its first-quarter 2002 financial results, showing a slight increase in revenue to $96.55 million from $91.43 million in the same period of the prior year. While overall revenue grew, net income saw a decrease to $7.19 million from $7.61 million in Q1 2001, with diluted earnings per share declining to $0.21 from $0.22. The company experienced growth in its Companion Animal Group (CAG) driven by increased sales of VetTest slides and reference laboratory services, though this was partially offset by lower sales of canine test kits and a specific treatment for ear mites. The Food and Environmental Group (FEG) also saw revenue growth, primarily from livestock and water testing products. A significant factor impacting the results was a $2.9 million pre-tax charge related to the CEO succession in January 2002. Additionally, the company adopted new accounting standards, notably SFAS No. 142, which ceased goodwill amortization and is expected to reduce future operating expenses, though it necessitates an impairment review.

Key Highlights

1Total revenue increased by 5.6% to $96.55 million for the first quarter of 2002, compared to $91.43 million in the first quarter of 2001.
2Net income decreased by 5.7% to $7.19 million in Q1 2002, down from $7.61 million in Q1 2001.
3Diluted earnings per share (EPS) decreased to $0.21 in Q1 2002 from $0.22 in Q1 2001.
4The Companion Animal Group (CAG) revenue grew by 4% to $76.43 million, primarily due to increased sales of VetTest slides and veterinary reference laboratory services.
5The Food and Environmental Group (FEG) revenue increased by 13% to $20.12 million, driven by livestock and water testing products.
6A pre-tax charge of $2.9 million related to CEO succession impacted the current quarter's results.
7The company adopted SFAS No. 142, ceasing goodwill amortization, which is expected to reduce future operating expenses and positively impact the effective tax rate.

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2002

Summary

Key Highlights

Frequently Asked Questions